[The clinical use of the new antioxidant thiotriazoline in ischemic ophthalmopathies].
The new antioxidant Thiotriazoline was used in the treatment of patients with retinal vascular occlusive processes. The agent improved retinal metabolism by inhibiting free radical oxidation. Thiotriazoline is superior to alpha-tocopherol acetate in its activity. Unlike the latter, it has no vasodilating effect.
Mazur
I A
IA
Maksimenko
S F
SF
Belenichev
I F
IF
Taranenko
D A
DA
Deriapa
I V
IV
Zavgorodniaia
N G
NG
D000208:Acute Disease; D000975:Antioxidants / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005123:Eye / Q000098:blood supply*; D005609:Free Radicals; D006801:Humans; D007511:Ischemia / Q000097:blood / Q000188:drug therapy*; D009900:Optic Nerve / Q000098:blood supply; D009901:Optic Nerve Diseases / Q000097:blood / Q000188:drug therapy; D010084:Oxidation-Reduction / Q000187:drug effects; D012164:Retinal Diseases / Q000097:blood / Q000188:drug therapy; D012169:Retinal Vein; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy; D014230:Triazoles / Q000627:therapeutic use*
D000975:Antioxidants; D005609:Free Radicals; D014230:Triazoles
Klinicheskoe primenenie novogo antioksidanta tiotriazolina pri ishemicheskikh oftal'mopatiiakh.